InvestorsHub Logo
Followers 9
Posts 569
Boards Moderated 0
Alias Born 10/08/2013

Re: Echo20 post# 110480

Wednesday, 04/22/2015 10:21:40 AM

Wednesday, April 22, 2015 10:21:40 AM

Post# of 146242
You mean this part...

NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model

Source: PR Newswire (US)
SHELTON, Conn., April 20, 2015 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal is now Professor Emeritus. He is a leading researcher in herpes virus anti-viral agents and vaccines.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News